Ebosin Ameliorates Psoriasis-Like Inflammation of Mice via miR-155 Targeting tnfaip3 on IL-17 Pathway

Guo, Weiwei; Xu, Fujuan; Zhuang, Zhuochen; Liu, Zhe; Xie, Jiming; Bai, Liping

doi:10.3389/fimmu.2021.662362

Cited by 12 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…345 MiR-155 is a central regulatory miRNA that is simultaneously involved in the regulation of multiple genes critical for functional epidermal development. 352 MiR-155 has been found upregulated in psoriatic skin lesions, LPS-induced keratinocytes, and monocytes [353][354][355][356][357] and to further regulate psoriatic processes, including the proliferation of psoriatic mesenchymal (PM) stem cells, the release of cytokines or chemokines of psoriatic keratinocytes, and Th17 inflammatory responses. With regard to the mechanism, miR-155 regulates the production of IL-6 and CXCL8 in keratinocytes through the GATA3/ IL-37 regulatory axis.…”

Section: Histone Modificationsmentioning

confidence: 99%

Signaling pathways and targeted therapies for psoriasis

Guo,

Zhang,

Lin

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on individuals, health systems, and society worldwide. With the immunological pathologies and pathogenesis of psoriasis becoming gradually revealed, the therapeutic approaches for this disease have gained revolutionary progress. Nevertheless, the mechanisms of less common forms of psoriasis remain elusive. Furthermore, severe adverse effects and the recurrence of disease upon treatment cessation should be noted and addressed during the treatment, which, however, has been rarely explored with the integration of preliminary findings. Therefore, it is crucial to have a comprehensive understanding of the mechanisms behind psoriasis pathogenesis, which might offer new insights for research and lead to more substantive progress in therapeutic approaches and expand clinical options for psoriasis treatment. In this review, we looked to briefly introduce the epidemiology, clinical subtypes, pathophysiology, and comorbidities of psoriasis and systematically discuss the signaling pathways involving extracellular cytokines and intracellular transmission, as well as the cross-talk between them. In the discussion, we also paid more attention to the potential metabolic and epigenetic mechanisms of psoriasis and the molecular mechanistic cascades related to its comorbidities. This review also outlined current treatment for psoriasis, especially targeted therapies and novel therapeutic strategies, as well as the potential mechanism of disease recurrence.

show abstract

Section: Histone Modificationsmentioning

confidence: 99%

Signaling pathways and targeted therapies for psoriasis

Guo,

Zhang,

Lin

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…The inhibition of NF-κB and reduction of downstream regulated cytokines has been proven as a mechanism of action for the anti-inflammatory and anti-psoriatic effects of a number of extracts, fractions or pure compounds in vitro and in vivo [42,53,54]. Blocking the NF-κB signaling and TNF-α (its canonical pathway inducer) is one of successful approaches of the anti-psoriasis treatment [40].…”

Section: Discussionmentioning

confidence: 99%

Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes

et al. 2021

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin condition characterized by abnormal keratinocyte proliferation and differentiation that is accompanied with dysregulated immune response and abnormal vascularization. Devil’s claw (Harpagophytum procumbens (Burch.) DC. ex Meisn.) tubers extract has been used both systemically and topically for treatment of chronic inflammatory diseases such as arthritis, osteoporosis, inflammatory bowel disease, among others. However, its potential mechanisms of action against psoriasis remains poorly investigated. The human keratinocyte HaCaT cell line is a well-accepted in vitro model system for inflammatory skin disorders such as psoriasis. The present study involved an exploration of the effect of biotechnologically produced H. procumbens (HP) cell suspension extract and pure phenylethanoid glycosides verbascoside (VER) and leucosceptoside A (LEU) in interferon (IFN)-γ/interleukin (IL)-17A/IL-22-stimulated HaCaT cells as a model of psoriasis-like inflammation. Changes in key inflammatory signaling pathways related to psoriasis development were detected by reverse transcription polymerase chain reaction and western blotting. Treatment with LEU, but not VER and HP extract improved psoriasis-related inflammation via suppression of the PI3K/AKT signaling in IFN-γ/IL-17A/IL-22-stimulated HaCaT cells. Our results suggest that LEU may exhibit therapeutic potential against psoriasis by regulating keratinocyte differentiation through inhibition of the PI3K/AKT pathway.

show abstract

“…139. This compound could mitigate lipopolysaccharide-activated inflammation in HaCaT via IκB kinase (IKK)/NF-κB signaling [ 124 ]. Moreover, the PASI score of the imiquimod-treated psoriasiform mice was decreased from 3 to 1.5 with the application of ebosin.…”

Section: Mirnas As the Targets To Inhibit Skin Inflammationmentioning

confidence: 99%

Anti-Inflammatory microRNAs for Treating Inflammatory Skin Diseases

et al. 2022

View full text Add to dashboard Cite

Skin inflammation occurs due to immune dysregulation because of internal disorders, infections, and allergic reactions. The inflammation of the skin is a major sign of chronic autoimmune inflammatory diseases, such as psoriasis, atopic dermatitis (AD), and lupus erythematosus. Although there are many therapies for treating these cutaneous inflammation diseases, their recurrence rates are high due to incomplete resolution. MicroRNA (miRNA) plays a critical role in skin inflammation by regulating the expression of protein-coding genes at the posttranscriptional level during pathogenesis and homeostasis maintenance. Some miRNAs possess anti-inflammatory features, which are beneficial for mitigating the inflammatory response. miRNAs that are reduced in inflammatory skin diseases can be supplied transiently using miRNA mimics and agomir. miRNA-based therapies that can target multiple genes in a given pathway are potential candidates for the treatment of skin inflammation. This review article offers an overview of the function of miRNA in skin inflammation regulation, with a focus on psoriasis, AD, and cutaneous wounds. Some bioactive molecules can target and modulate miRNAs to achieve the objective of inflammation suppression. This review also reports the anti-inflammatory efficacy of these molecules through modulating miRNA expression. The main limitations of miRNA-based therapies are rapid biodegradation and poor skin and cell penetration. Consideration was given to improving these drawbacks using the approaches of cell-penetrating peptides (CPPs), nanocarriers, exosomes, and low-frequency ultrasound. A formulation design for successful miRNA delivery into skin and target cells is also described in this review. The possible use of miRNAs as biomarkers and therapeutic modalities could open a novel opportunity for the diagnosis and treatment of inflammation-associated skin diseases.

show abstract

Ebosin Ameliorates Psoriasis-Like Inflammation of Mice via miR-155 Targeting tnfaip3 on IL-17 Pathway

Cited by 12 publications

References 50 publications

Signaling pathways and targeted therapies for psoriasis

Signaling pathways and targeted therapies for psoriasis

Leucosceptoside A from Devil’s Claw Modulates Psoriasis-like Inflammation via Suppression of the PI3K/AKT Signaling Pathway in Keratinocytes

Anti-Inflammatory microRNAs for Treating Inflammatory Skin Diseases

Contact Info

Product

Resources

About